Definium Therapeutics (DFTX) Operating Income (2019 - 2026)

Definium Therapeutics (DFTX) has 7 years of Operating Income data on file, last reported at -$59.2 million in Q1 2026.

• Operating Income for Q1 2026 came in at -$59.2 million, down 84.15% year-over-year; the trailing twelve-month figure through Mar 2026 was -$193.4 million (down 69.81% YoY), and the FY2025 annual result was -$166.3 million, down 60.04% from the prior year.
• Operating Income retreated to -$59.2 million in Q1 2026 per DFTX's latest filing, from -$47.6 million in the prior quarter.
• Over five years, Operating Income peaked at -$13.9 million in Q4 2022 and troughed at -$59.2 million in Q1 2026.
• A 5-year average of -$28.8 million and a median of -$24.5 million in 2024 frame the typical range for Operating Income.
• On a YoY basis, Operating Income climbed as much as 62.53% in 2022 and fell as far as 124.6% in 2022.
• A 5-year view of Operating Income shows it stood at -$13.9 million in 2022, then tumbled by 59.75% to -$22.2 million in 2023, then plunged by 46.19% to -$32.5 million in 2024, then tumbled by 46.57% to -$47.6 million in 2025, then fell by 24.47% to -$59.2 million in 2026.
• Business Quant data shows DFTX's Operating Income at -$59.2 million in Q1 2026, -$47.6 million in Q4 2025, and -$45.7 million in Q3 2025.